IO Before BRAK/MEK Inhibition Is the Ideal Treatment Sequence for BRAF-Mutant Melanoma
Source: Targeted Oncology, October 2022
Data from the DREAMseq trial have answered a lingering question of how to sequence therapy for patients with advanced BRAF-mutant melanoma. This research supports immunotherapy in the first-line setting, followed by BRAK/MEK inhibitors.
For most patients with advanced BRAF-mutant melanoma, the treatment sequence of nivolumab (Opdivo) in combination with ipilimumab (Yervoy) followed by a BRAF and MEK inhibitor is the optimal sequencing, according to Michael B. Atkins, MD, et al, investigators of the DREAMseq trial (NCT02224781).
Prior to the study, the was no clear sequencing path for PD-1 and CTLA-4 therapies combined with BRAK/MEK inhibition due to a lack of data from prospective studies.